HSV Patient Engagement study
Research type
Research Study
Full title
A study of the characteristics of patients diagnosed with recurrent symptomatic genital herpetic disease
IRAS ID
315654
Contact name
Kerstin Westritschnig
Contact email
Sponsor organisation
Rational Vaccines Inc
Duration of Study in the UK
0 years, 6 months, 11 days
Research summary
The sponsor, Rational Vaccines Inc, is developing a vaccine against Herpes Simplex Virus for use in patients suffering from recurrent genital herpes.
The Sponsor would like to engage with patients suffering from genital herpes prior to the finalisation of the clinical trial protocols to better understand the current treatment landscape in the UK. They would also like to assess the acceptance of this group of patients for at-home testing, visit frequency, and preferences for telemedicine follow-up visits.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
22/EM/0114
Date of REC Opinion
3 Aug 2022
REC opinion
Further Information Favourable Opinion